AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
The last earnings update was 29 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
AC Immune. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
AC Immune's earnings available for a low price, and how does
this compare to other companies in the same industry?
AC Immune's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
AC Immune's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
AC Immune's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPartners AG and is its Partner. She serves as an Advisor at the Nestlé Venture Capital Fund, which she co-founded. She has 25 years of senior management experience with broad research and development, business and international focus. She served as the Head of Nestlé’s Global Research and Development and managed a group of more than 600 people. She headed the Science and Technology Alliances group at Nestlé SA. While at Nestlé, she led the scientific development of the first Functional Food, LC1 and one of the first Cosmoceutical products in a joint venture with L'Oreal, Innéov Fermeté. Prof. Dr. Pfeifer directed the research department for life sciences, nutrition, food science and food safety and various other departments. She serves as Chairwoman at AB2 Bio Ltd., BioMedInvest AG I and BioMedInvest AG II. She serves as Chairwoman of the Biotechmedinvest AG Investment Fund, Basel. She has been a Member of the Supervisory Board at Symrise AG since May 18, 2011. She has been a Director of AC Immune SA since May 27, 2016. She served as a Member of Supervisory Board at Sygnis AG until October 17, 2012. She served as a Member of Supervisory Board at Sygnis Pharma AG from December 18, 2006 to October 17, 2012. She is a Member of the CEOi Initiative on Alzheimer’s Disease. She is also a Member of various Commissions and Boards, including the German Senate Commission on Food Safety, the Board of Directors of the Research Center for Environment and Health and the Swiss Association for Trade and Industry. She is an Honorary Professor at the Ecole Polytechnique Fédérale de Lausanne, Switzerland. She is a Lecturer at the IMD Business School in Lausanne and a Professor of Biotechnoloy at the University of Lausanne. She holds a professorship from the Federal Institute of Technology at Lausanne. She has published more than 200 papers and abstracts in leading scientific journals. In 2009, she was recognized as a Technology Pioneer by the WEF and Swiss Entrepreneur of the Year by Ernst&Young. Additional recognitions include the BioAlps prize 2013, the election as one of the top 10 women in biotech from Fierce Biotech and one of the 300 most influential personalities in Switzerland. She is a registered Pharmacist and Toxicologist and received her habilitation from the University of Lausanne, Switzerland. She is an international expert in biotechnology. She holds a Ph.D. in Toxicology and Cancer Research and a B.S. degree in Pharmacy from the University of Würzburg, Germany and continued with post-doctoral work in Molecular Carcinogenesis at the National Institutes of Health, Human Carcinogenesis Branch in Bethesda, USA.
Insufficient data for Andrea to compare compensation growth.
Insufficient data for Andrea to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the AC Immune management team is about average.
Chief Financial Officer
Head of Technical Operations & Program Management
Chief Scientific Officer
Chief Administrative Officer
Head of Regulatory & External Affairs and Senior Expert
Head of Biology
Head of Chemistry
Head of Chemistry
Head of AD - SME
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the AC Immune board of directors is less than 3 years, this suggests a new board.
Board of Directors
Chairman of Scientific Advisory Board
Independent Non-Executive Director
Fred Van Leuven
Member of Scientific Advisory Board
Member of Scientific Advisory Board
Independent Non-Executive Director & Member of Scientific Advisory Board
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer’s disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics, as well as Nestlé Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.